Willingsford

Willingsford is a UK-based healthcare company that develops and manufactures advanced wound care and dermatological products. The company's core technology, SertaSil, consists of microporous particles that facilitate wound healing through a non-pharmacological, physical mechanism by removing exudate, bacteria, and toxins. Their product line includes SertaSil for chronic and acute wounds, AcuSil for skin conditions such as acne and rosacea, and specialized veterinary treatments. Willingsford's approach focuses on providing evidence-based, cost-effective solutions that reduce the need for antibiotics and improve patient outcomes. The company serves both the human healthcare and veterinary markets globally.